Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Potentially Harmful Drugs in Young Adults with HFrEF

Am J Cardiol; ePub 2019 Feb 9; Alvarez, et al

Nearly one-fourth of adults patients with a diagnosis of heart failure with reduced ejection fraction (HFrEF) have a prescription of a drug with a potential to cause or exacerbate heart failure, a new study found. Prescription of potentially harmful drugs (PHD) was examined among patients with a HFrEF diagnosis in: 2 outpatient encounters; 1 inpatient encounter as primary diagnosis; and/or 1 inpatient encounter any position and 1 outpatient encounter. Among the details:

  • Among 40,966 patients, 24.2% were prescribed with at least 1 drug with the potential to cause or exacerbate HF.
  • Of the 9,954 patients prescribed with PHD, nonsteroidal anti-inflammatory agents were the most frequent category prescribed.
  • In multivariable analysis, female patients, the presence of a comorbidity associated with a PHD use, and polypharmacy were more frequently prescribed a PHD.

Citation:

Alvarez PA, Truong CN, Briasoulis A, Ganduglia-Cazaban C. Prescription of potentially harmful drugs in young adults with heart failure and reduced ejection fraction. [Published online ahead of print February 9, 2019]. Am J Cardiol. doi:10.1016/j.amjcard.2019.01.052.